IHP Therapeutics is developing IHP-102, a dual P-selectin and complement inhibitor designed for the treatment of acute vaso-occlusive crises in sickle cell disease. This self-administered therapeutic aims to reduce pain symptoms and tissue damage, enabling patients to manage their condition at home rather than relying on healthcare facilities.
Funding
$36.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with sickle cell disease (SCD) often experience acute vaso-occlusive crises (VOCs) characterized by severe pain and tissue damage. Current treatments typically require visits to healthcare facilities, placing a burden on both patients and the healthcare system. There is a need for therapies that can be self-administered at home to reduce reliance on emergency care.
Solution
IHP Therapeutics is developing IHP-102, a novel therapeutic designed for self-administration to treat acute VOCs in SCD patients. IHP-102 is a dual inhibitor of P-selectin and complement, two key mechanisms driving vaso-occlusion in SCD. By blocking these mechanisms, IHP-102 aims to reduce pain symptoms and mitigate tissue and organ damage associated with VOCs. The therapeutic is intended to empower patients to manage their condition at home, avoiding costly and overburdened healthcare systems.
Target Audience
The primary target audience includes individuals with sickle cell disease who experience acute vaso-occlusive crises, as well as healthcare providers seeking to improve patient outcomes and reduce the burden on healthcare facilities.
Features
- Dual inhibition of P-selectin and complement pathways
- Designed for self-administration in a home setting
- Aims to reduce pain symptoms associated with vaso-occlusive crises
- Intended to decrease tissue and organ damage caused by VOCs
- Potential to reduce the need for hospital visits